We are developing a Universal Cancer Vaccine (UCV) that will use the body’s own immune system to target and eliminate cancer cells. The UCV will use cutting edge bioengineering and molecular technologies to uniquely detect, mark and kill only cancer cells. By forcing cancer cells to express a unique marker that healthy cells do not have, custom antibody drugs and the body's immune system can target and destroy them with precision. Additionally, we intend to make cancer cell look like common diseases so that the body’s immune system can destroy them with ease. We have filed a patent application for the UCV and are partnering with UCLA to develop the platform, which may be administered as a one or two-shot treatment.
We are developing a disease-specific immunotherapy targeted at treating Ewing Sarcoma, a
rare but deadly bone and soft tissue cancer that primarily affects children and young
adults and for which there is no current FDA approved treatment for recurrence.
We have entered into a sponsored research agreement with the University of California at Los Angeles (UCLA) to develop effective immunotherapies, such as CAR T-cell and monoclonal antibodies, for Ewing Sarcoma. We have the exclusive right to negotiate and license any resulting intellectual property and have also entered into a Letter of Intent with UCLA to negotiate a license for a pre-existing patent application. UCLA is a top-ranked university known for its cancer research and medical school.
Our team of dedicated scientists is on the cutting edge of cancer research. From the lab to the clinic, we are committed to finding new and better ways to prevent and treat cancer.
Years of collective
Dr. Jonas is a UCLA physician-scientist specializing in pediatric hematology/oncology. He received a bachelor’s degree in materials science & engineering and a master’s degree in biomedical engineering prior to starting his medical training to pursue his M.D. and Ph.D. degrees at UCLA through its NIH-supported Medical Scientist Training Program. He leads a multidisciplinary research team that targets the development and application of new nanotechnologies and methods to support the childhood cancer and regenerative medicine communities in accelerating the discovery of innovative gene therapy approaches.
Dr. De Oliveira is a board-certified pediatrician and board-certified pediatric hematology/oncologist. He received his medical degree in Brazil and completed his pediatric residency at Woodhull Medical and Mental Health Center in New York and his pediatric hematology/oncology fellowship at the Children’s Hospital Lost Angeles. His clinical focus is on pediatric oncology and gene therapies and his research focus is on cancer immunotherapy and biology of stem cell transplantation.
Dr. Seet is a hematologist and oncologist subspecializing in the treatment of hematologic malignancies, including hematopoietic stem cell transplantation, cellular therapy and clinical trials of novel therapeutics. He received a undergraduate degree in Biological Science at the University of Chicago, a medical degree at the University of Sydney, Australia and PhD in Cellular and Molecular Pathology at UCLA. His research focuses on human T cell and dendritic cell tumor immunology, and the development of engineered stem cell-based approaches to cancer therapy.
Dr. Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA. He specializes in treating children, adolescents and young adults with these aggressive cancers. He runs a multidisciplinary program involving pediatric and medical oncologists, radiation oncologists, orthopedic oncology surgeons, musculoskeletal radiologists and pathologists, nuclear medicine specialists, physical therapists and prosthetic specialists. He received a medical degree from the Icahn School of Medicine at Mount Sinai and completed his residency and fellowship at UCLA.
Dr. Denny has served as a physician at UCLA for over 3 decades primarily focused on pediatric oncology. He has trained and mentored some of UCLA’s best and brightest scientists and doctors in the field. Dr. Denny received a bachelor’s degree from University of Pennsylvania and a medical degree from the University of Pennsylvania School of Medicine. He completed his residency at the Children’s National Medical Center and fellowship at the National Institutes of Health Clinical Center. Most of Dr. Denny’s academic success has come through applying basic molecular biology tools to seek molecular mechanisms for what he witnesses when treating pediatric hematology/oncology patients.
Dr. Ryan Looper, a chemistry Professor at the University of Utah, sat down with CancerVAX CEO Ryan Davies to discuss the future of novel therapeutics and how the industry can encourage young scientists to enter the field.
Dr. Jonathan Lakey, Professor in University of California – Irvine’s Surgery and Biomedical Engineering departments, spoke with CancerVAX CEO Ryan Davies on his accomplishments in scientific research and their impact on the world
The UCLA research team, which includes Dr. Steven Jonas, Dr. Christopher Seet, Dr. Satiro De Oliveira and Dr. Christopher Denny, will leverage cutting-edge technologies to develop a breakthrough universal cancer vaccine (UCV) that will train the body to target and destroy cancer cells.